O
OnKure
Developing treatments for cancer
About OnKure
OnKure Therapeutics is a clinical-stage biopharmaceutical company that focuses on the development of precision medicines for cancer. The company targets cancers with PI3Kα mutations, which are among the most common oncogenic mutations.
OnKure's business model revolves around the discovery and development of targeted oncology therapeutics. The company aims to create "best-in-class" treatments that are highly selective for mutations, which could lead to better efficacy and fewer side effects for patients. The company is publicly traded on Nasdaq (OKUR) and recently completed a merger with Reneo Pharmaceuticals, along with a $65 million private placement, to fund its clinical trials and research and development activities. Its lead product candidate, OKI-219, is currently in a Phase 1b/2 clinical trial (PIKture-01) for the treatment of various solid tumors with PI3Kα mutations.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- Boulder, United States
- Employees
- 41
- Open positions
- None listed
- Dealroom signal
- 72.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Investment activity
- 1 company, latest May 2024
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | May 2024 | $0 | — | Undisclosed | ↗ |
| LATE VCOther financing | Mar 2023 | $54M | $275M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for OnKure is 2.6K monthly website visits, down 7.1% over the last three months. OnKure's team grew 7.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Delian Capital
Citadel
Samsara BioCapital
BlackRock
Cormorant Asset Management
Perceptive Advisors
Acorn Bioventures
Other known investors2 additional known investors
University of Colorado
RiverVest Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about OnKure on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OnKure’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.